Table 3.
Luteolin and its antioxidant property in neurodegenerative disease models.
| Relevant studies ↓ | Molecule | Study samples | Neurodegenerative disease | Effect |
|---|---|---|---|---|
|
Current Study Abuelnor Mohammed et al., 2023 (unpublished) |
Luteolin | Neuroblastoma Cells |
Huntington Disease |
Activation of Nrf2-OH1 |
| He et al., 2023 | Luteolin | Triple transgenic AD (3 × Tg-AD) mice | Alzheimer’s disease | Luteolin treatment increased both the antioxidants SOD activity and GSH levels while decreasing the level of MDA. Also, UCP2, a key part of the mechanism preventing ROS production and plays a vital role in protecting neurons from oxidative stress, levels were increased in luteolin treated Alzheimer’s diseased mice compared to wild type mice. |
| Reudhabibadh et al., 2021 | Luteolin | Neurotoxicity induction by 1-methyl-4-phenylpyridinium iodide (MPP + ), a neurotoxin in neuroblastoma SH-SY5Y cells | Parkinson’s Disease | Treatment with luteolin significantly attenuated MPP + -induced O2 − elevation compared to the MPP + treated group. Also, luteolin reduced MPP + induction of MDA, a biomarker of oxidative damage and O2 − levels, compared to the control group. |
| Siddique, 2021 | Luteolin | Transgenic fly lines that expresses first coding exon of human htt | Huntington’s disease | The activity of GSH, SOD and CAT in luteolin exposed Huntington’s diseased flies was increased compared to controls. |
| Siddique et al., 2018 | Luteolin | Transgenic fly (Drosophila) lines that express wild-type human synuclein |
Parkinson’s disease | PD flies exposed to luteolin showed an increase in the GSH activity in a dose dependent manner while a decrease in protein carbonyl content and lipid peroxidation compared to unexposed flies. |